SCHEMBL2223120

SCHEMBL2223120

CC1=C(C(=Cc2ccc([S+](C)[O-])cc2)C(=O)O)c2cc(F)ccc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 4/20 0.38
▸ AKR1C3 P42330 4/20 0.37
▸ AKR1C2 P52895 3/20 0.37
▸ AKR1C1 Q04828 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PPARG P37231 1/20 0.31
▸ MAOA P21397 1/20 0.30
▸ MAOB P27338 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ GLA P06280 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ EDNRA P25101 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8506321 1.00 PTGS2 (0.38) PTGS2AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL15572432 0.90 PTGS2 (0.34) PTGS2AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL15571625 0.89 AKR1C3 (0.37) PTGS2AKR1C3AKR1C2AKR1C1MAOA
SCHEMBL15570939 0.89 PTGS2 (0.37) PTGS2AKR1C3AKR1C2AKR1C1MAOA
SCHEMBL2221809 0.87 AKR1C3 (0.37) PTGS2AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL15572558 0.87 AKR1C3 (0.40) PTGS2AKR1C3
SCHEMBL15570465 0.85 AKR1C3 (0.39) AKR1C3ALDH1A1MEN1KMT2AMAOB
SCHEMBL8796929 0.85 MAOA (0.34) PTGS2AKR1C3ALDH1A1MEN1KMT2A
SCHEMBL2223831 0.85 PTGS2 (0.32) PTGS2AKR1C3AKR1C2AKR1C1
SCHEMBL8428502 0.84 PTGS2 (0.38) PTGS2AKR1C3AKR1C2AKR1C1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882426-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2015-06-17 — — EP disclosed
WO-2014026959-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2014-02-20 — — WO disclosed
WO-2011088474-A2 SULINDAC AND SULINDAC DERIVATIVES AND THEIR USES RELATED TO INFECTION Zirus, Inc. (US) 2011-07-21 — — WO disclosed
WO-2005068411-A1 PROCESS FOR THE PREPARATION OF 6-FLUORO-2-METHYL-1-INDANONE ZAMBON GROUP S.P.A. (IT) 2005-07-28 — — WO disclosed
Send feedback